National HealthCare Corporation filings document operating results, dividend actions, governance matters and capital-structure disclosures for a publicly traded senior health care company. The company’s 8-K reports include earnings releases, quarterly common dividend announcements, director appointments and other material-event disclosures, with NHC common stock registered on the NYSE American.
Proxy materials cover annual meeting matters, shareholder voting, board structure and committee governance. The filing record also describes NHC’s skilled nursing, senior living, behavioral health, home care, hospice, pharmacy, rehabilitation and third-party management activities, along with financial reporting topics such as GAAP and non-GAAP results, marketable equity securities and acquired White Oak operations.
NATIONAL HEALTHCARE CORP director Sandra Y. Trail exercised stock options and increased her direct share holdings. On May 6, 2026, she exercised options to acquire 3,140 shares of common stock at an exercise price of $55.75 per share, bringing her direct ownership to 10,640 shares.
Trail continues to hold multiple option grants. These include a 2023 grant with 4,360 options remaining, plus 2024, 2025, and 2026 grants, each tied to 7,500 underlying shares with exercise prices between $94.66 and $171.42 and expirations from 2029 through 2031. The options were granted under the company’s 2020 Omnibus Equity Incentive Plan and are exempt from Section 16(b) under Rule 16b-3(d).
National Healthcare Corp director William A. Adams received a grant of options to purchase 7,500 shares of common stock. The options have an exercise price of $171.42 per share, matching the closing price on May 7, 2026, and are scheduled to expire on May 6, 2030. This Form 4/A corrects a previous filing that had mistakenly reported the option price as $0.00, while the number of options and underlying shares remains 7,500.
National HealthCare Corporation reported higher first quarter 2026 results. Net operating revenues for the quarter ended March 31, 2026 were $381.8 million, up from $373.7 million a year earlier, an increase of 2.2%.
GAAP net income attributable to NHC rose to $35.9 million from $32.2 million, while adjusted net income increased to $30.1 million from $24.8 million, a 21.1% gain. GAAP diluted EPS were $2.27 versus $2.07, and adjusted diluted EPS were $1.91 versus $1.59.
Cash, cash equivalents and marketable securities totaled $258.4 million at March 31, 2026, and current and long‑term debt were reduced to $0 from $40.0 million at December 31, 2025. The quarterly dividend per share increased to $0.64 from $0.61, supported by steady skilled nursing volumes and higher average per‑diem rates.
NATIONAL HEALTHCARE CORP director Sandra Y. Trail reported a compensation-related award of stock options. She received an option to purchase 7,500 shares of common stock at an exercise price of $171.42 per share, granted under the 2020 Omnibus Equity Incentive Plan on May 7, 2026.
The option becomes exercisable on May 7, 2027 and expires on May 6, 2031. Following this filing, Trail holds 7,500 shares of common stock directly and has several prior option grants outstanding with exercise prices of $94.66, $96.03, and $55.75 per share, each covering 7,500 underlying shares. The company notes the grant and its potential exercise are exempt from Section 16(b) under Rule 16b-3(d).
NATIONAL HEALTHCARE CORP director James Paul Abernathy reported an equity award and updated holdings. He received an option to purchase 7,500 shares of common stock at an exercise price of $171.42 per share, expiring on May 6, 2031. The options were granted under the 2020 Omnibus Equity Incentive Plan and are described as exempt from Section 16(b) under Rule 16b-3(d).
Following the reported entries, he directly holds 43,302 shares of common stock. He also holds previously granted options covering 7,500 shares at $94.66, 7,500 shares at $96.03, and 4,360 shares at $55.75, providing additional potential future share exposure if exercised.
National Healthcare Corp director William A. Adams received a grant of options on 7,500 shares of common stock. The options were granted on May 7, 2026 under the company’s 2020 Omnibus Equity Incentive Plan with a stated exercise price of $0.00 per share and expire on May 6, 2030. Following this award, Adams holds options covering 7,500 shares directly as reported in this filing. The grant and potential exercise are described as exempt from Section 16(b) under Rule 16b-3(d), indicating this is a routine equity-based compensation award for a board member.
National Healthcare Corp director David R. Gifford received a new stock option grant. He was granted options to purchase 7,500 shares of NHC common stock at an exercise price of $171.42 per share. The options were granted under the 2020 Omnibus Equity Incentive Plan and are scheduled to expire on May 6, 2030. The grant is reported as a compensation-related award and is exempt from Section 16(b) under Rule 16b-3(d).
National Healthcare Corp director Lisa Piercey received a grant of stock options as compensation. On May 7, 2026, she was awarded options to purchase 7,500 shares of common stock at an exercise price of $171.42 per share, expiring on May 6, 2030. The options were granted under the company’s 2020 Omnibus Equity Incentive Plan, with no cash paid at grant, and leave her holding 7,500 options following the transaction.
National Healthcare Corp director Robert G. Adams reported a new stock option grant. He received options covering 7,500 shares of common stock at an exercise price of $171.42 per share, expiring on May 6, 2031.
The options were granted on May 7, 2026 under the company’s 2020 Omnibus Equity Incentive Plan, with no cash paid for the grant. The filing also lists existing option awards from 2022–2025 and indirect holdings of common stock in a trust and a partnership, but no open‑market share purchases or sales.
NATIONAL HEALTHCARE CORP director Emil E. Hassan received a new stock option grant as part of equity compensation. On May 7, 2026, he was granted options to purchase 7,500 shares of common stock at an exercise price of $171.42, vesting beginning May 7, 2027 and expiring May 6, 2031, under the 2020 Omnibus Equity Incentive Plan. Following this grant, he directly holds 73,095 shares of common stock and several prior option awards, each covering 7,500 shares at exercise prices of $94.66, $96.03, $55.75, and $69.19 with expirations from 2027 through 2030.